Strategic financing Recent Series C of 70M plus ongoing funding history indicates strong investor confidence and a runway to expand radiopharmaceutical programs; target BD opportunities with investors and co-development deals in solid tumor radiopharmaceuticals.

Manufacturing expansion Expanded manufacturing collaboration with PharmaLogic and a planned Salt Lake City radiopharmaceutical facility suggest a growing need for contract manufacturing, supply chain partners, and scale-up capabilities for radiolabeled therapeutics.

Theranostics focus Trillium targeting platform enables both imaging and therapeutic isotopes, creating cross-sell opportunities with diagnostic radiology and targeted therapy teams, as well as potential collaborations with imaging agents and companion diagnostics developers.

Clinical leadership New CMO appointment signals a push toward advancing clinical development; engage with Ratio for advisory roles, trial design partnerships, and co-development discussions around Ac-225 RTX-2358 and related candidates.

Campus and capacity build Long-term facility project in Utah aimed for 2027 completion creates opportunities for regional partnerships, vendor alliances, and supply agreements around radiopharmaceutical manufacturing, regulatory readiness, and exclusivity arrangements.